Biochemical Target and Mechanism of Action
Upon entering the body, the prodrug (mycophenolate mofetil) undergoes metabolic conversion to release the active substance — mycophenolic acid. At the biochemical level, this compound acts as a highly selective and fully reversible inhibitor of a specific enzyme called inosine monophosphate dehydrogenase (IMPDH).
Under normal physiological conditions, the enzyme IMPDH plays a key role in purine metabolism. It catalyzes a critical reaction: the conversion of inosine monophosphate (IMP) to xanthosine monophosphate. The latter, in turn, is the direct biochemical precursor of guanosine monophosphate (GMP).
When mycophenolic acid blocks IMPDH, this cascade is interrupted. As a result, the synthesis of guanosine nucleotides via the de novo pathway drops sharply inside the cell. Because purine nucleotides are essential building blocks for creating new nucleic acid chains, their deficiency inevitably leads to the suppression of DNA synthesis. Without DNA replication, full cell division becomes impossible.
Rationale for Selectivity of Action
The pharmacological value of mycophenolic acid lies in its selectivity. The drug primarily suppresses the proliferation of immune cells, namely T lymphocytes and B lymphocytes.
This selectivity is explained by the characteristics of cellular metabolism. Specifically, for T and B lymphocytes, de novo purine synthesis is critically important and practically the only way to obtain material for DNA construction. With GMP deficiency caused by IMPDH blockade, lymphocytes lose their ability to proliferate, which provides a potent immunosuppressive effect.
At the same time, other cells in the human body possess metabolic flexibility. To obtain the necessary nucleotides, they are able to utilize alternative biochemical routes — the so-called salvage pathways. Due to these bypass routes, most body tissues suffer significantly less from the effects of mycophenolic acid compared to the lymphocytic lineage.
Indications for Clinical Use
The drug has found widespread application in two major medical fields: transplantology and rheumatology.
- Solid organ transplantation. Mycophenolate mofetil is included in immunosuppressive therapy regimens to prevent graft rejection following heart, kidney, and liver transplantation.
- Autoimmune diseases. The drug is used in maintenance therapy for systemic lupus erythematosus. In addition, it is used to treat idiopathic thrombocytopenic purpura.
Important pharmacological feature: in the treatment of systemic lupus erythematosus and idiopathic thrombocytopenic purpura, the drug is prescribed in lower doses, unlike the high-dose therapy used in organ transplantation.
Side Effects and Contraindications
Despite its high lymphocyte selectivity, therapy with mycophenolic acid can cause a range of adverse reactions. Side effects most commonly affect systems with actively dividing cells:
- Gastrointestinal tract (GIT): patients frequently complain of dyspeptic symptoms, including nausea, vomiting, and diarrhea.
- Hematopoietic system: bone marrow suppression manifests as changes in complete blood counts, primarily the development of anemia and leukopenia.
An absolute contraindication to prescribing mycophenolic acid is pregnancy. The drug has significant teratogenic potential and can cause irreversible harm to the developing fetus.